Bladder cancer treatment registry for organ preservation
Part of Cancer clinical trials.
This study is for people with muscle-invasive bladder cancer who have had chemotherapy or other systemic therapy before surgery, but have chosen not to have their bladder removed. It aims to track different treatment approaches to help preserve the bladder and understand outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can give informed consent.
- You have been diagnosed with muscle-invasive bladder cancer (urothelial carcinoma) that has spread into the muscle layer of the bladder.
- You have received systemic therapy (like chemotherapy or immunotherapy) before surgery, as part of your treatment plan.
- You have decided not to have your bladder removed (cystectomy) or receive radiation therapy after that systemic therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a bladder-sparing treatment plan that uses MRI to guide therapy for muscle-invasive bladder cancer. It combines maximal tumor removal, chemotherapy, and radiation to avoid bladder removal.
This trial uses advanced MRI scanning to guide treatment decisions for muscle invasive bladder cancer. It aims to improve outcomes by personalizing therapy based on detailed imaging.
This trial tests a combination of probiotics, targeted therapy, and immunotherapy aimed at preserving the bladder in people with muscle-invasive bladder cancer. It's for those who can't have standard surgery or cisplatin chemo, and whose tumors have a certain protein (HER2).
This trial tests a bladder-sparing approach for people with muscle-invasive bladder cancer that has a variant histology type. The goal is to avoid removing the bladder by using a combination of treatments.
This study tests a combination of chemotherapy, immunotherapy, and radiation to treat muscle-invasive bladder cancer while trying to avoid bladder removal. It compares this approach to a watch-and-wait strategy, and also looks at adding maintenance immunotherapy.
This study follows people with muscle-invasive bladder cancer who choose to keep their bladder (instead of removing it) after receiving chemotherapy, immunotherapy, or an ADC drug. It aims to see how well this approach works and what side effects may occur.
Hear when a new Muscle Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.